Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma
International Journal of Clinical Oncology · 2025-06 · 30 (6) · 1118-1126
DOI: 10.1007/s10147-025-02739-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 17.03.2025. Verfasst von Toshihiko Sakai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. tsakai8312@gmail.com. Hauptthemen laut MEDLINE: Salvage Therapy, Mouth Neoplasms, Neoplasm Recurrence, Local, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BACKGROUND: The prognosis of patients with locally recurrent oral cavity squamous cell carcinoma (LR-OCSCC) remains poor even when salvage surgery can be performed. Therefore, the current study aimed to identify adverse prognostic factors in these patients and use recursive partitioning analysis (RPA), a machine learning statistical method, to develop a prognostic classification based on these factors. METHODS: The clinical data of 75 patients who underwent salvage surgery for LR-OCSCC at the National Cancer Center between 2010 and 2022 were retrospectively reviewed. Prognostic factors were analyzed using Cox proportional hazards regression models. Patients were classified by survival outcomes using RPA. Survival rates were determined using the Kaplan-Meier method. RESULTS: The 3-year overall survival (OS) and locoregional recurrence rates for all patients who underwent salvage surgery were 53.4% and 32.7%, respectively. The univariate Cox proportional hazards regression analysis identified concurrent regional recurrence, previous history of radiotherapy to the neck, and recurrence within 12 months from initial treatment as adverse prognostic factors. RPA was performed using these variables and patients were classified into low-, intermediate-, and high-risk groups based on a combination of concurrent regional recurrence and time to recurrence. The 3-year OS rates for the low-, intermediate-, and high-risk groups were 73.3%, 53.3%, and 24.4%, respectively. CONCLUSION: A novel prognostic classification for LR-OCSCC salvage surgery was developed to facilitate development of treatment strategies and identification of patients that would not benefit from this procedure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. tsakai8312@gmail.com.
- Department of Head and Neck Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sakai, T., Omura, G., Eguchi, K., Sakai, A., Matsumoto, Y., Fushimi, C., & Yoshimoto, S. (2025). Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma. International Journal of Clinical Oncology, 30(6), 1118-1126. https://doi.org/10.1007/s10147-025-02739-9
Vancouver
Sakai T, Omura G, Eguchi K, Sakai A, Matsumoto Y, Fushimi C, et al. Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma. International Journal of Clinical Oncology. 2025;30(6):1118-1126. doi:10.1007/s10147-025-02739-9
BibTeX
@article{Sakai2025,
author = {Sakai, Toshihiko and Omura, Go and Eguchi, Kohtaro and Sakai, Azusa and Matsumoto, Yoshifumi and Fushimi, Chihiro and Yoshimoto, Seiichi},
title = {Prognostic prediction using recursive partitioning analysis of patients undergoing salvage surgery for locally recurrent oral squamous cell carcinoma},
journal = {International Journal of Clinical Oncology},
year = {2025},
volume = {30},
number = {6},
pages = {1118--1126},
doi = {10.1007/s10147-025-02739-9}
}
EUVIMED